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Background: The aim of the study was to evaluate the effects of universal mass vaccination (UMV) against rotavirus
(RV) on the hospitalization rates, nosocomial RV infections and RV-gastroenteritis (GE)-associated secondary blood
stream infections (BSI).
Methods: The retrospective evaluation (2002–2009) by chart analysis included all clinically diagnosed and
microbiologically confirmed RV-GE cases in a large tertiary care hospital in Austria. The pre-vaccination period
(2002–2005) was compared with the recommended and early funded (2006–2007) and the funded (2008–2009)
vaccination periods. Primary outcomes were RV-GE-associated hospitalizations, secondary outcomes nosocomial RV
disease, secondary BSI and direct hospitalization costs for children and their accompanying persons.
Results: In 1,532 children with RV-GE, a significant reduction by 73.9% of hospitalized RV-GE cases per year could
be observed between the pre-vaccination and the funded vaccination period, which was most pronounced in the
age groups 0–11 months (by 87.8%), 6–10 years (by 84.2%) and 11–18 years (88.9%). In the funded vaccination
period, a reduction by 71.9% of nosocomial RV-GE cases per year was found compared to the pre-vaccination
period. Fatalities due to nosocomial RV-GE were only observed in the pre-vaccination period (3 cases). Direct costs
of hospitalized, community-acquired RV-GE cases per year were reduced by 72.7% in the funded vaccination period.
The reduction of direct costs for patients (by 86.9%) and accompanying persons (86.2%) was most pronounced in
the age group 0–11 months.
Conclusions: UMV may have contributed to the significant decrease of RV-GE-associated hospitalizations, to a
reduction in nosocomial RV infections and RV-associated morbidity due to secondary BSI and reduced direct
hospitalization costs. The reduction in nosocomial cases is an important aspect considering severe disease courses
in hospitalized patients with co-morbidities and death due to nosocomial RV-GE.
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Rotavirus (RV) infections are one of the most frequent
causes of gastroenteritis in children worldwide with a
major impact on mortality in children <2 years living in
developing countries [1-4]. In European countries, mor-
tality attributed to RV infections was estimated to be 1
in 100,000 children <5 years for each year [5-7], with a
high burden of nosocomial RV gastroenteritis in the
pediatric population [8].
In Austria, about 45,000 episodes of acute RV-associated
gastroenteritis (RV-GE) account for approximately 1,400
hospital admissions per 100,000 children [2,5]. Austria,
prompted by cost calculations [9], was one of the first
European countries to recommend vaccination against RV
since 2006 and to subsidize an universal mass vaccination
(UMV) program in infants aged between 6 weeks and 6 -
months with Rotateq (Sanofi Pasteur MSD SNC, Lyon,
France; market launch September 2006) between July
and December 2007 and with Rotarix (GlaxoSmithKline
Biologicals, Rixensart, Belgium; market launch May 2006)
between January 2008 and December 2009. Both vaccines
are directed against the most important serotypes circulat-
ing in Austria, G1P (74.0%), G4P (8.0%) and G3P (1.8%)
which were found in samples from hospitalized children
due to RV-GE in Innsbruck, Tyrol, and Leoben, Styria
[10]. A vaccination coverage of 72 to 87% was documented
by surveillance data in 2008 [11]. The hospitalized cases in
RV-affected children aged between 3 and 20 months
decreased from August 2007 until December 2008 by 74%
[11]. A further reduction of RV-GE and some effects of
herd protection in older children who were not covered
by the UMV because of age limitations were described
for 2009 [12]. Both commercially available RV vaccines
have a similar efficacy and safety profile [1,13] and have
been found to be cost-effective depending on different
perspectives and modeling assumptions in some European
and developing countries [13-17] with a reduction of
all-cause diarrhea-related hospitalizations among children
<5 years [18-22].
From the patho-physiological view, RV causes an intes-
tinal epithelium dysfunction in the small intestine. RV-
damaged enterocytes are more capable for bacterial in-
vasion causing secondary bacterial infections [23,24].
Only few studies exist thus far which focus on secondary
blood stream infections (BSI) as one major and life-
threatening complication following RV-GE [24-29].
The retrospective evaluation by chart analysis (2002–
2009) focused on all both clinically diagnosed and
microbiologically confirmed RV-GE-associated cases in a
large tertiary care children’s hospital in Austria. The
focus was on RV-GE-associated hospitalizations as the
primary outcomes; secondary outcomes were the
burdens of nosocomial RV disease and occurrence of
secondary BSI as well as direct hospitalization costs forchildren and their accompanying persons based on the
accounts provided by the clearing office of the hospital.
Methods
Study design and study population
The retrospective evaluation focused on all cases of RV-
GE hospitalized between 1st January 2002 and 31st
December 2009 at the Department of Pediatrics, Medical
University Innsbruck, a tertiary hospital with additional
primary and secondary care functions, covering the area
of Tyrol with an average population of 1,277,775
inhabitants between 2002 and 2009. For our analysis, all
RV positive stool samples from the Division of Hygiene
and Medical Microbiology and the Routine Laboratory
of the Department of Pediatrics were matched with the
data from the hospital discharge records using the Inter-
national Classification of Diseases, 10th edition (ICD-10)
with search terms “gastroenteritis” (K52.9), “rotavirus”
(A08.0), “exsiccosis” (A09) and “blood stream infection”
(A41.9) as primary and secondary diagnosis to identify
potential RV cases. For inclusion into the study, clinical
diagnosis of RV infection had to be confirmed by labora-
tory results. For included patients a chart review was
performed.
Subgroups of the study population
Groups were separated into a “pre-vaccination period”
(January 2002 to December 2005), a “recommended and
early funded vaccination period” (intermediate period)
(January 2006 to December 2007) and a “funded vaccination
period” (January 2008 to December 2009). For determin-
ation of the influence of UMV on the age distribution and
the hospitalization rates in children with RV infections, chil-
dren were separated into 5 different age groups according to
epidemiological data: infants aged 0–11 months, toddlers
aged 12–23 months, children aged 2–5 years, school chil-
dren aged 6–10 years and children 11–18 years of age. The
reasons for age classification are: Most children acquire their
first RV-GE before the age of 5 years [1-7]. Severe RV-GE
is largely limited to children aged <24 months [1,2].
Vaccinated children aged between 0 and 11 months should
have received at least one dose of the vaccine. Toddlers aged
between 7 and 24 months are most likely to have been fully
vaccinated during UMV [9]. The RV vaccination status
could not be collected by chart review. Double-counters
and patients admitted more than once due to RV-GE
were excluded.
The study was performed according to the principles
of the declaration of Helsinki 2008 and the local ethics
committee of the Innsbruck Medical University.
Data collection and definitions
Clinical data from patients included into the study were
collected by chart analysis. Cases were defined as
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of gastroenteritis-specific symptoms (diarrhea, vomiting)
was at least 48 hours after admission to hospital [9]
considering an incubation time for RV of 18–36 hours
[30] and an admission diagnosis that was not “gastro-
enteritis”. Gastroenteritis was defined by more than
3 loose stools or watery diarrhea within 24 hours [3]
with or without vomiting (particularly in older children),
fever and dehydration according to signs given in a scor-
ing system for RV GE [31]. The duration of the hospital
stay was defined as the time span between the day of
admission and the day of discharge. Nosocomial RV-GE
cases were excluded from the analysis of hospital
stay durations.
A blood stream infection (BSI) was defined as at least
one of the following features: first, a blood culture positive
for a pathogen; second, a common pathogen of human
skin cultured from two or more blood cultures, both
drawn on separate occasions; or third, a common patho-
gen of the human skin cultured from at least one blood
culture in association with signs of a systemic inflamma-
tory response syndrome (SIRS). A SIRS was defined by at
least two of the following criteria: elevated body
temperature >38°C or hypothermia <36°C, tachycardia,
tachypnea, leucocytosis, leukopenia or >10% immature
neutrophils according to age ranges. A secondary BSI was
defined as a BSI following the clinical symptoms of gastro-
enteritis associated with laboratory confirmed RV infec-
tion more than 48 after onset of RV-associated disease.
The present study focused exclusively on secondary BSI.
Hygienic regulations for prevention of nosocomial
infections on the ward were not changed during 2002 to
2009. All nurses and doctors with direct contact to the
RV-infected patient had to wear over-coats and had to
follow a three minutes long hand washing program with
Bode SterilliumW Virugard (Paul Hartmann AG, Telgte,
Germany) disinfectant solution after patient contact.
RV-positive patients and their accompanying persons
were cohorted on the ward in separate rooms with own
bath rooms and were prohibited to use any facilities on
the ward which may have offered the possibility to get in
contact with other patients.
Laboratory confirmation of RV and other pathogens from
stool samples
Between 2002 and 2009, all hospitalized patients with
gastroenteritis were screened for RV antigen in their stools.
For detection of human RV antigen in stool specimen the
Pathfinder Direct Antigen Detection System (Kallestad La-
boratories, Inc. Austin, Texas) was used till 2005. The sensi-
tivity and specificity of this test system is 84% and 98%,
respectively. After 2005, the CerTestRota Card (Biotec,
Zaragoza, Spain), an immunochromatographic test for
Rotavirus detection in stool specimen was used for routinetesting. The sensitivity and specificity of this test system is
>99% and 98%, respectively. Routinely, stools were also
investigated for additional viral pathogens (Norovirus,
Adenovirus) via antigen detection and for bacterial
pathogens (Salmonella, Yersinia, Shigella, Campylobacter
spp. and enterohemorrhagic Escherichia coli) via stool
cultures according to standard procedures.
Identification of pathogens in blood culture
From patients showing at least two signs of SIRS, an
average of 4 ml blood was drawn for detection of blood-
stream pathogens and inoculated into a BacT/Alert PF
Pediatric FAN bottle (BioMérieux, Durham, USA). This
procedure did not change over the observation period.
The bottles were then loaded into a BacT/Alert 3D
automated blood culture system (BioMérieux) for a five
day protocol with monitoring of carbon dioxide produc-
tion within each bottle every 10 min. All bottles marked
positive were removed from the instrument, and an ali-
quot was taken for Gram staining and culture on solid
media for subsequent analysis. Pathogen identification
was performed according to standardized microbial
procedures and by VITEK 2 system (BioMérieux).
Cost calculations
The direct hospitalization costs for children and their ac-
companying persons are based on the accounts provided by
the clearing office of the “Tiroler Landeskrankenanstalten”
(TILAK) holding. For the pre-vaccination period the mean
of the costs were 870 € per patient per day and for the
accompanying person 35 € per day given a proportion
of 87.2% accompanying persons in children <6 years
(funded vaccination period: 930 €, 38 € and 90.8%, respect-
ively). Children ≥6 years of age are usually not accompanied
due to the insurance system which does not refund parents’
costs for the hospital stay together with their child. Nosoco-
mial infections were excluded from cost calculations be-
cause of co-morbidity-associated costs which do not allow
an approximation of hospitalization costs. Estimated mean
of costs per year for community-acquired RV-GE cases
were calculated by multiplication of the mean hospital
duration (days) (Table 1), mean number of patients per year
per age-group (Table 2), mean of direct costs (€) and
proportion of accompanying persons in age groups
<6 years. Costing procedures have not changed during the
study period.
Calculation of hospitalization rates
The Innsbruck hospital covers approximately 70% of all
pediatric RV-GE hospitalizations in Tyrol. estimated
hospitalization rates were calculated for the pre-
vaccination, the intermediate and funded vaccination
period using the draw area of Tyrol for patients 0–
18 years for the different periods (pre-vaccination
Table 1 Clinical and laboratory characteristics of patients with secondary BSI
Type of
RV-GE
(number)
Mean age
(months; range)
Sex
(female/male)
Onset of BSI
after RV-GE
(hours; range)
Underlying
disease
(number)
Pathogens in
blood culture
(number)
Other pathogens in
stool samples
(number)
Mean CRP
(mg/dl; range)
Community-
acquired (6)
13.9 (11–60) 2/4 149 (48–384) WPW-syndrome (1) Staphylococcus
aureus (2)
Negative (6) 3.6 (0.2–17.1)
Bronchitis (1) Neisseria species (1)
None (4) Enterobacter
species (3)
Klebsiella species (1)
Pseudomonas
aeruginosa (1)
Nosocomial
(14)
15.6 (0.2–60) 6/8 189 (48–648) Preterm birth (7) Staphylococcus
aureus (10)
Negative (12) 9.4 (0.3–19.3)
SOT (2) Streptococcus
pneumoniae (1)
Clostridium
difficile (2)
ALL (3) Enterobacter
species (2)
Adenovirus (1)
Gastroschisis (1) Enterococcus
faecalis (1)
Propionacetemia (1)
Abbreviations: Rotavirus-gastroenteritis (RV-GE); Wolff-Parkinson-White-syndrome (WPW); solid organ transplantation (SOT); acute lymphatic leukemia (ALL);
C-reactive protein (CRP).
Preterm birth was defined by gestational age <37 weeks. In some patients more than one pathogen was found. There was no significant difference between the
community-acquired and nosocomial RV-GE groups.
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vaccination period: 305,393) [31] as denominator for cal-
culation of incidence rates.
Statistical analysis
Statistical analysis was performed with SPSS Version 18.0
(Chicago, IL). Non-parametric Mann-Whitney-U test was
used to compare mean hospitalizations per year between
the pre-vaccination and the vaccination period. Pearson’s
Chi-square test was used to analyze difference in dichotome
variables. A p < 0.05 was defined statistically significant.
Results
Effectiveness of RV vaccination
During the study period, a total number of 3,090 RV-
positive stool samples were collected. After excludingTable 2 Reduction of RV-GE in age groups from the pre-vacci
Pre-vaccination period (2002–2005) Intermediate period
Numbers of
patients (%)
Mean numbers/
year (95% CI)
Numbers of
patients (%)
Mea
yea
0–11 mos 360 (35.1) 90.0 (80.2–99.8) 113 (30.4) 56.5
12–23 mos 300 (29.2) 75.0 (62.8–87.2) 125 (33.6) 62.5
2–5 yrs 254 (24.8) 63.5 (50.8–76.2) 110 (29.6) 55.0
6–10 yrs 76 (7.4) 19.0 (15.1–22.9) 19 (5.1) 9.5
11–18 yrs 36 (3.5) 9.0 (4.1–13.9) 5 (1.3) 2.
All 1026 (100) 256.5 (222.2–290.8) 372 (100) 186.0
Abbreviations: mos months, yrs years, CI confidence interval.
aReduction is calculated between mean numbers per year of the pre-vaccination pedouble-counters, 2,533 remaining RV-positive cases were
matched with the documented ICD-10 discharge codes.
A total of 1,001 RV-positive cases were excluded as there
was no clinical diagnosis of RV-GE in these patients.
The mean age of the RV-GE afflicted 1,532 patients
(809 male, 723 female) was 2.3 years (median 1.4 years;
range 3 days–16.5 years) (Table 2). A significant reduc-
tion of hospitalized RV-GE cases per year could be
observed between the pre-vaccination and the funded
vaccination period (p < 0.001) (Table 2, Figure 1). The
absolute number of mean cases per year decreased
most strongly in children below 6 years of age
(Figure 1). The proportional reduction of hospitalized
RV-GE cases per year and age group was most
pronounced in the age groups 0–11 months, 6–10 years
and 11–18 years (Table 2).nation period to the funded vaccination period
(2006–2007) Funded vaccination period (2008–2009) Reductiona
n numbers/
r (95% CI)
Numbers of
patients (%)
Mean numbers/
year (95% CI)
Decreased
by (%)
(44.7–68.3) 22 (16.4) 11.0 (2.7–19.3) 87.8
(37.6–87.4) 55 (41.1) 27.5 (7.4–47.6) 63.3
(36.5–73.5) 48 (35.8) 24.0 (11.5–36.5) 62.2
(8.3–10.7) 6 (4.5) 3.0 (1.6–4.4) 84.2
5 (1.8–3.4) 3 (2.2) 1.0 (0.8–2.2) 88.9
(119.5–252.5) 134 (100) 67.0 (22.7–111.3) 73.9
riod and the funded vaccination period (decrease in percentage).
Figure 1 Numbers of hospitalized RV-GE cases.
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cases were nosocomial compared to the pre-vaccination
period (p < 0.001) (Table 3). The absolute number of mean
nosocomial cases per year decreased most strongly in the
age group 0–11 months (Table 3). The proportional re-
duction was most pronounced in the age groups 0–
11 months, 6–10 years and 11–18 years (Table 3, Figure 2).
There was no change in seasonal peaks of RV-GE between
the pre-vaccination and the other periods (Figure 3).
In 2003 to 2005, 3 patients died because of nosocomial
RV-GE due to deterioration of their underlying diseases
and co-morbidity (tetralogy of Fallot; transplantation of
the small intestine and secondary BSI with multi-organ
failure; Rett-syndrome). No patient died because of RV-
GE in the other periods.
Searching for co-infections, in the pre-vaccination
period, at least one additional pathogen was detected in
the stool samples of 41 (4.0%) out of 1026 patients with
confirmed RV-GE (mean 10.3 cases per year; 95% CI
8.4–12.1) and in the stool samples of 13 (9.7%) out of
134 patients (mean 6.5 cases per year; 95% CI 3.7–9.3)
in the vaccination period (p < 0.01). Overall, the most
frequent co-infecting pathogens were adenovirus (36
cases), Salmonella ssp. (26 cases), norovirus (18 cases)
and Campylobacter (12 cases).
Secondary BSI after RV-GE occurred in 20 cases (pre-
vaccination period: 14 cases, 1.4% out of 1026 patients;
intermediate period: 3 cases, 0.8% out of 372 patients;
funded vaccination period: 3 cases, 2.2% out of 134patients) (Table 1), with 14 cases (70%) found in patients
with nosocomial RV-GE. All patients were younger than
6 years with a mean C-reactive protein at the occurrence
of BSI specific symptoms of 5.3 mg/dl. The most fre-
quently detected pathogens were Staphylococcus aureus
(60.0%), followed by Enterobacteriaceae. RV viremia was
reported in one case.
Hospitalization rates, duration of hospital stay and cost
calculations
Hospitalization rates were reduced from an annual mean
of 55.3/10,000 person-years in the pre-vaccination
period and 11.6/10,000 person-years in the intermediate
period to 4.3/10,000 person-years in the funded vaccin-
ation period (reduction by 92.2%).
The mean duration of hospital stay for community-
acquired RV-GE cases was shorter in the funded vaccin-
ation period compared to the pre-vaccination period (p <
0.01), which was most pronounced in the 6–10 years old
children (p < 0.01) (Table 4). The mean duration of hos-
pital stay for nosocomial RV-GE cases was 8.0 days (95%
CI: 7.7–8.4) in the pre-vaccination period, 9.8 days (95%
CI: 6.9–12.7) in the intermediate period and 13.3 days
(95% CI: 5.8–20.7) in the funded vaccination period.
In the funded vaccination period, total direct costs
were reduced by 72.7% compared to the pre-vaccination
period (p < 0.01) (Table 4). The reduction of direct costs
for patients and accompanying persons was most
pronounced in the age group 0–5 months.
Table 3 Reduction of community-acquired and nosocomial RV-GE in age groups
Age Pre-vaccination period (2002–2005) Intermediate period (2006–2007) Funded vaccination period (2008–2009) Reductiona
Total numbers
(% of total numbers)
Numbers per year
(mean; 95% CI)
Total numbers
(% of total numbers)
% of pre-vaccination Total numbers
(% of total numbers)
Numbers per year
(mean; 95% CI)
Decreased
by (%)
CA NO CA NO CA NO CA NO CA NO CA NO CA NO
0–11 mos 303 (32.9) 57 (53.8) 75.8 (67.7–83.8) 14.3
(12.2–16.3)
94 (27.9) 19 (59.4) 47.0 (37.3–56.7) 9.5 (7.4–11.6) 21 (16.3) 1(25.0) 10.5 (1.5–19.5) 0.5
(-0.2–1.2)
86.1 96.5
12–23 mos 279 (30.4) 21 (19.8) 69.8 (57.8–81.8) 5.3 (4.3–6.3) 113 (33.5) 9 (28.1) 58.0 (56.6–59.4) 4.5 (2.4–6.6) 53 (41.1) 2 (50.0) 26.5 (6.4–46.6) 1.0 (0–1) 62.0 81.1
2–5 yrs 234 (25.4) 20 (18.9) 58.5 (46.3–70.8) 5.0 (3.8–6.2) 106 (31.5) 4 (12.5) 53.0 (51.6–54.4) 2.0 (-0.8–4.8) 46 (35.7) 1 (25.0) 23.5 (11.7–35.3) 0.5 (-0.2–1.0) 59.8 90.0
6–10 yrs 71 (7.7) 5 (4.7) 17.8 (13.9–21.6) 1.3 (0.6–2.0) 19 (5.6) 0 9.5 (1.9–17.1) 0 6 (4.6) 0 3.0 (1.6–4.4) 0 83.1 100
11–18 yrs 33 (3.6) 3 (2.8) 8.3 (3.6–12.9) 0.8 (0.5–1.1) 5 (1.5) 0 2.5 (1.8–3.2) 0 3 (2.3) 0 1.5 (0.8–2.2) 0 81.9 100
All 920 (100) 106 (100) 229.5
(196.7–262.3)
26.5
(24.1–29.0)
337 (100) 32 (100) 170.0 (160.7–178.6) 16.0 (13.2–18.8) 129 (100) 4 (100) 64.5 (20.8–108.2) 2.0 (0–2.0) 71.9 92.5
Abbreviations: mos months, yrs years, CA community-acquired, NO nosocomial, CI confidence interval.
aReduction is calculated between mean numbers per year of the pre-vaccination period and the funded vaccination period (decrease in percentage).
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Figure 2 Numbers of community-acquired and nosocomial RV-GE cases.
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The present study clearly demonstrates that UMV not only
led to reduction of RV-GE-associated hospitalizations by
73.9%, but also to a pronounced reduction of nosocomial
RV infections by 92.5%. The possible indirect effect of
UMV on nosocomial RV infections may be an important
aspect considering severe disease courses in hospitalized
patients with co-morbidities. This was corroborated by the
fact that mortality in our pre-vaccination cohort wasFigure 3 Seasonal distribution and monthly numbers of hospitalized
January 2002 to December 2005, the recommended and early funded vacc
2007 and the funded vaccination period from January 2008 to December 2
September 2006 (dotted lines and arrows). Rotateq was subsidized by the
Rotarix was subsidized by the UVM January 2008 to December 2009 (contiattributed to deterioration of the underlying disease by
nosocomial RV infection. A reduction of nosocomial RV in-
fection was also seen in the US shortly after introduction of
RV vaccination [32].
Also, in our study, secondary BSI was, in the majority
of cases, linked to nosocomial RV-GE. In infants, RV
infection has been described as a cause of pneumatosis
intestinalis, hemorrhagic gastroenteritis, necrotizing
enterocolitis and secondary BSI with mainly pathogensRV-GE cases. In the study, the pre-vaccination period lasts from
ination period (intermediate period) from January 2006 to December
009. Rotarix was launched May 2006 and Rotateq was launched
universal mass vaccination (UVM) program July to December 2007,
nuous lines and arrows) in Austria.
Table 4 Duration and total costs for all community-acquired RV-GE induced hospital stays in the study hospital
Age Pre-vaccination period (2002–2005) Funded vaccination period (2008–2009) Reduction
Duration of hospital
stay (days) per year
(mean; 95% CI)
Estimated mean of total
costs per year (for patients/
accompanying persons)
Duration of hospital
stay (days) per year
(mean; 95% CI)
Estimated mean total
costs per year (patient/
accompanying person)
Duration of
hospital stay
decreased by (%)
Costs per
year
decreased
by (%)
0–11 mos 3.4 (3.1–3.7) 224,216 €/ 7,865 € 3.0 (2.3–3.6) 29,295 €/ 1,087 € 11.8 86.9/86.2
12–23
mos
4.0 (3.6–4.3) 242,904 €/ 8,521 € 3.5 (3.4–3.5) 86,256 €/ 3,201 € 12.5 64.5/62.4
2–5 yrs 3.7 (3.6–3.9) 188,312 €/ 6,608 € 3.5 (3.1–3.8) 76,493 €/ 2,838 € 5.4 59.4/57.1
6–10 yrs 4.1 (3.7–4.4) 63,493 €/0 2.5 (1.8–3.2) 6,975 €/0 39.0 -
11–18 yrs 3.9 (2.8–4.9) 28,162 €/0 3.8 (2.7–4.8) 5,301 €/0 2.6 -
All 3.8 (3.5–4.1) 747,087 €/22,994 € 3.3 (2.7–3.8) 204,320 €/ 7,126 € 13.2 72.7/69.0
Calculation:
Pre-vaccination group: Estimated mean of total costs per year = annual mean number of patients with community-acquired RV-GE in the respective age group x
mean duration of hospital stay x mean cost per patient/accompanying person.
Post-vaccination group: mean of total costs per year = annual mean number of patients with community-acquired RV-GE in the respective age group x mean
duration of hospital stay x mean cost per patient/accompanying person.
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of the Enterobacteriaceae family [24-29,33,34]. In our
cohort, many of the 20 patients with secondary BSI
were preterm infants or patients with compromised im-
mune system and showed BSI due to Staphylococcus
aureus. These findings allow us to hypothesize that not
only intestinal mucosa dysfunction due to RV-GE
promotes transition of intestinal bacteria, but that also
a fatal combination of severe underlying diseases with
dehydration and malnutrition in succession of RV-GE
could have made patients more prone for secondary
BSI caused also by non-intestinal bacteria. Although
both RV vaccines cover the most important serotypes
even in Austria [11], so far we are not able to know
whether a shift to other RV serotypes will take place in
the future causing inefficiency of the vaccine serotypes
[35,36] and whether other gastroenteritis pathogens
will take over.
The reduction of community-acquired hospitalized
RV-GE cases found in our study confirms the data of
recently published studies [5,11,12] which showed a
significant reduction of RV cases reported by sentinel
hospitals in the vaccination period in all age groups. In
our study, the age group 0–11 months had the highest
benefit of vaccination, highlighting the importance of
starting the vaccination as early as possible [12]. A
clear reduction in the older individuals indicates the
presence of herd protection in the population by reduc-
tion of RV transmission [12,37,38]. However, also trans-
mission of the attenuated RV types from vaccinated
children to unvaccinated individuals may induce some
immunity against RV in the unvaccinated older popula-
tion [39-41].
In the US, a 50% decrease in RV-positive laboratory
tests has been found after recommendation of RV vac-
cination for routine use in 2006, showing a delay inseasonal onset of the RV season 2007–2008 by 2–4 -
months [2]. These data are in contrast to our data and
previous data from Austria [11] which could not detect
a shift of RV-associated hospitalizations to later months.
However, the findings of the US study are limited by
missing data from the end of the RV season 2007–2008
and by the fact that RV was tested based on the discre-
tion of the physicians and local policies.
In our cohort, we could demonstrate a reduction of
mean annual real costs by 72.7% between the pre-
vaccination and the funded vaccination period, although it
was not possible to include indirect costs, such as work
loss by parents staying with the hospitalized child and
supervision of siblings staying at their own. Considering
the direct and indirect costs of hospital admissions due to
RV-GE, UMV programs have been shown to be cost-
effective [42] and would lead to a reduction of costs for
RV-GE-related hospitalizations/emergency visits by 83%
and for medical consultations by 75% [43]. In our study, in
the funded vaccination period, hospital stays were about
half a day shorter than in the pre-vaccination period which
may also be accounted for by milder disease courses [44].
Limitations of our study exist in the fact that only
hospitalized cases were counted and that local health-
seeking behaviors of the population and hospital-specific
guidelines for admission may influence the hospitalization
rates [3]. We here reported the results of a single, large,
tertiary care center and might have consistently missed
mild cases of RV-GE which were treated at home. One
disadvantage of a single-center experience also exists for
differences in incidence oscillations by seasonal forcing
and demographic forcing that may cause different patterns
of hospitalizations in different places. Certainly not all RV
cases would have been detected and might have been
influenced by different detection systems and coding
practices. The detection system was changed in 2005 to a
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itionally, the nature of the disease itself has to be taken
into account, as wild-type RV infection does not prevent
re-infection, or does not consequently enhance protection
against recurrent infection [45-47]. However, the relative
risk of re-infection is lower after one RV infection (0.62),
two infections (0.4) or three subsequent infections (0.34)
[47]. Subsequent infections are often subclinical or mild
[47] and will not consequently lead to hospitalization of
the children. Milder and asymptomatic cases will be less
infectious, both as a result of reduced viral shedding rate
and a shorter duration of infection. Thus, vaccination will
cause fewer infections by making vaccinated individuals
less able to become re-infected, if vaccination elicits the
same immunological response as natural infections, and
less able to transmit RV to others as predicted by trans-
mission dynamic models [48]. In addition, also the
numbers of older children may be underestimated, as
most of them will suffer from mild infection without need
for hospitalization [11]. Hospitalized re-infections were
not assessed in our study, as double-counters were
excluded to avoid biasing our results. Interestingly, in our
study, 557 patients were double-counters, however, most
of them were repeated detections of RV antigen in the
stool samples during the same hospital stay or in immuno-
compromised patients showing a slow clearance from in-
testinal RV replication [41]. Unfortunately, due to the
retrospective character of our study, the vaccination status
was not sufficiently documented in the investigated patients,
thus, despite being certainly of interest, break-through RV
infections could not be assessed. Natural epidemiological
oscillations are other factors which might have influenced
our results. However, epidemiological studies since 1997
based on a sentinel system showed that fluctuations of RV-
GE numbers were always less than the decrease observed
since introduction of UMV [5]. An unrecognized change in
the prevention of pathogen transmission was excluded in
our study, as similar hygienic rules and introduction of
nurses, parents and visiting persons were applied during the
whole study period, interventions which have been shown
to be crucial in reduction of transmission [20].
Conclusions
In conclusion, UMV against RV may have contributed to
the significant decrease of hospitalizations of RV-GE
since 2008 [11,12] and, most important, to a reduction of
nosocomial RV infections and RV-associated morbidity due
to secondary BSI and reduced direct hospitalization costs.
The reduction in nosocomial cases is an important aspect
considering severe disease courses in hospitalized patients
with co-morbidities and death due to nosocomial RV-GE.
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